Levodopa/carbidopa intestinal gel, neuropathy, and B-vitamins – Is there an association?
Objective: To assess the frequency of neuropathy and its neurophysiological characteristics in orally and levodopa/carbidopa intestinal gel (LCIG) treated patients with advanced idiopathic Parkinson´s disease…Peri-operative dopaminergic replacement protocol with rotigotine in Parkinson’s disease patients
Objective: To evaluate the accomplishment of a peri-operative dopaminergic replacement protocol established in our centre from 2011 to 2014, and analyse the main factors associated…Exploratory efficacy of opicapone in fluctuating Parkinson’s disease patients at different stages of symptom progression
Objective: Evaluate the efficacy of opicapone (OPC) in fluctuating Parkinson's disease patients at different stages of symptom progression over a 14-15 week treatment period. Background:…Continuous subcutaneous delivery of solubilized carbidopa improves the pharmacokinetic profile of levodopa
Objective: To characterize the peripheral pharmacokinetics and CNS metabolism of levodopa during continuous subcutaneous delivery of solubilized carbidopa. Background: Although many commercial levodopa formulations include…Effects of plantar automated mechanical stimulation (AMPS) on motor symptoms of patients with advanced Parkinson’s disease: Preliminary data of a double blind randomized clinical trial
Objective: To evaluate the effect of one session treatment with autometed mechanical peripheral stimulation (AMPS) on gait and motor functions of patients with advanced Parkinson's…Long-term safety of levodopa-carbidopa intestinal gel from an ongoing, open-label, phase 3 continued access to treatment study in advanced Parkinson’s disease patients
Objective: To assess the safety and tolerability of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) in advanced Parkinson's disease…Extended-release carbidopa-levodopa, IPX066: Dosing and efficacy with concomitant medication use in Parkinson’s disease
Objective: Evaluate the efficacy and dosing of IPX066 in patient groups taking concomitant Parkinson's disease (PD) medication, using post hoc subgroup analyses. Background: IPX066 is…Rasagiline treatment for sleep disorders in Parkinson’s disease (RaSPar) – Double-blinded, randomized, placebo-controlled, placebo run-in-phase, polysomnography clinical trial
Objective: To study the effects of Rasagiline on sleep disturbances measured by polysomnographic (PSG) evaluation of sleep efficacy and secondary measures as other sleep variables,…Efficacy of apomorphine subcutaneous injections in patients with levodopa dose failures and morning akinesia
Objective: To assess the effect of subcutaneous injection of apomorphine (APO) in patients with Parkinson's disease (PD)and morning akinesia who experience dose failures after their…A clinical trials ‘charter’ to improve communication about, recruitment to and retention in Parkinson’s clinical trials
Objective: The objective of the project was to design a durable tool, usable by clinical trial investigators and participants alike, that would improve subject retention…
- « Previous Page
- 1
- …
- 135
- 136
- 137
- 138
- 139
- …
- 207
- Next Page »